Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

PubWeight™: 4.48‹?› | Rank: Top 1%

🔗 View Article (PMID 28578607)

Published in N Engl J Med on June 04, 2017

Authors

Karim Fizazi1, NamPhuong Tran1, Luis Fein1, Nobuaki Matsubara1, Alfredo Rodriguez-Antolin1, Boris Y Alekseev1, Mustafa Özgüroğlu1, Dingwei Ye1, Susan Feyerabend1, Andrew Protheroe1, Peter De Porre1, Thian Kheoh1, Youn C Park1, Mary B Todd1, Kim N Chi1, LATITUDE Investigators

Author Affiliations

1: From Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); Janssen Research and Development, Los Angeles (N.T.), Beerse, Belgium (P.D.P.), San Diego, CA (T.K.), and Raritan, NJ (Y.C.P.); Instituto de Oncologia de Rosário, Rosário, Argentina (L.F.); National Cancer Center Hospital East, Chiba, Japan (N.M.); 12 de Octubre University Hospital, Madrid (A.R.-A.); P.A. Hertsen Moscow Cancer Research Institute, Moscow (B.Y.A.); Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey (M.Ö.); Fudan University Shanghai Cancer Center, Shanghai, China (D.Y.); Studienpraxis Urologie, Nürtingen, Germany (S.F.); Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom (A.P.); Janssen Global Services, Raritan, NJ (M.B.T.); and BC Cancer Agency, Vancouver, Canada (K.N.C.).

Associated clinical trials:

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | NCT01715285

Articles citing this

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med (2017) 1.43

Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.31

Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.27

Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 0.96

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination. Radiat Oncol J (2017) 0.75

Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect (2017) 0.75

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials (2017) 0.75

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer. Indian J Urol (2017) 0.75

Improved Outcomes in Men with Advanced Prostate Cancer. N Engl J Med (2017) 0.75

Prostate cancer: STAMPEDE, LATITUDE and Fernand Labrie's legacy. Nat Rev Urol (2017) 0.75

Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer (2017) 0.75

Prostate cancer: A new standard-of-care for advanced-stage disease. Nat Rev Clin Oncol (2017) 0.75

Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. Clin Cancer Res (2017) 0.75